[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"receptor-fibroblast-growth-factor-type-3\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:receptor-fibroblast-growth-factor-type-3":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100656559","phase-2-a-study-of-vepugratinib-ly3866288-in-adults-with-non-muscle-invasive-bladder-cancer-and-upper-tract-urothelial-cancer-100656559",false,"NCT07827612","A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer","FORAY: A Phase 2, Randomized, Open-Label Study Evaluating Vepugratinib in Adults With FGFR3 Altered Low Grade, Intermediate Risk, Non-muscle Invasive Bladder Cancer and Low Grade Upper Tract Urothelial Carcinoma","FORAY","Inclusion Criteria:\n\n* All Participants:\n\n  * Have a PS of 0 to 2 on the Eastern Cooperative Oncology Group Performance Status (ECOG PS) scale\n* Cohort A\n\n  * Have histologically confirmed LG NMIBC.\n  * Have LG IR NMIBC at time of screening\n  * Have a documented qualifying fibroblast growth factor receptor 3 protein (FGFR3) mutation or fusion\n* Cohort B\n\n  * Have histologically confirmed LG UTUC.\n\nExclusion Criteria:\n\n* All Participants\n\n  * Have had a prior positive urine cytology within 6 weeks of first day of treatment.\n  * Have received prior local instillation (for example, intravesical chemotherapy, Bacillus Calmette-Guerin, Jelmyto) therapy within 8 weeks of the first day of treatment.\n* Cohort A\n\n  * Have synchronous UTUC disease.\n  * Have presence of, or history of, high-grade urothelial carcinoma within 3 years of the first day of treatment, or presence of, or history of, carcinoma in situ.\n* Cohort B\n\n  * Have presence of bladder tumors at the time of enrollment.\n  * Have presence of, or history of, high-grade urothelial carcinoma or carcinoma in situ.","ALL","18 Years",{"count":20,"type":21},161,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The main purpose of this study is to see how well vepugratinib works in adults with low grade, intermediate risk, non-muscle invasive bladder cancer (LG IR NMIBC) or low-grade upper tract urothelial carcinoma (LG UTUC). Safety tests will also be conducted.\n\nFor each participant, the study will last up to 5 years.",[27,28,29],"Urinary Bladder Neoplasms","Urologic Neoplasms","Receptor, Fibroblast Growth Factor, Type 3","NOT_YET_RECRUITING","2026-10-07",{"date":33,"type":34},"2026-10-08","ACTUAL",{"date":36,"type":21},"2026-12",{"date":38,"type":21},"2031-03",{"name":40,"class":41},"Eli Lilly and Company","INDUSTRY"]